Your session is about to expire
← Back to Search
AZD0171 + Durvalumab + Chemotherapy for Pancreatic Cancer
Study Summary
This trial will test a new combination of drugs to treat pancreatic cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have brain metastases or spinal cord issues related to my cancer.I don't have any major side effects from previous treatments, except for possible skin or hair issues, or controlled diabetes.I have or had an autoimmune or inflammatory disorder.I haven't received any live vaccines in the last 28 days, except for non-live COVID-19 vaccines.I am fully active or restricted in physically strenuous activity but can do light work.I have had a heart attack, stroke, or similar event in the last 3 months.My cancer shows a specific immune response.I do not have any unmanaged ongoing illnesses.My body weight is at least 35 kg.I have not had a blood clot in the last 3 months.I have previously received immunotherapy.I have been diagnosed with a type of pancreatic cancer that has spread.I have not taken any cancer treatment before starting this study.I do not have an active infection and tested negative for COVID-19 recently.I have had another type of cancer.I haven't taken immunosuppressive drugs in the last 14 days.I have had a solid organ transplant.My cancer shows a specific immune response.My body weight is at least 35 kg.My organ and bone marrow functions are normal.I have been diagnosed with a type of pancreatic cancer that has spread.My organ and bone marrow functions are normal as tested within the last 28 days.I am fully active or restricted in physically strenuous activity but can do light work.My pancreatic cancer has a specific mutation that responds well to standard treatments.
- Group 1: AZD0171 + Durvalumab + chemotherapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the maximum capacity for participants in this experiment?
"Affirmative. Clinicaltrials.gov conveys that this research, which was initially posted on December 10th 2021, is currently seeking participants. 115 individuals are expected to be recruited from 25 separate medical centers."
Is there a sizeable presence of this trial within North America?
"This clinical trial is taking place in 25 medical centres across the nation, including Newton, Grand Rapids and Charlottesville. It would be beneficial to choose a clinic that is nearby your residence if you decide to participate, so as to minimize travel requirements."
Does this clinical study encompass individuals under the age of twenty-five?
"The criteria for entry into this study calls for participants to be older than 18 and more youthful than 130."
What aims is this medical study attempting to accomplish?
"Investigating the efficacy of this intervention is the primary purpose of this clinical trial. Until 90 days post-treatment, overall survival at 12 months (OS-12) will be monitored as a measure of success. Secondary outcomes include investigations into terminal elimination half-life, median overall survival and maximum observed plasma concentration for AZD0171, durvalumab and chemotherapy treatments or their metabolites."
Is enrolment to this trial still accessible for patients?
"Clinicaltrials.gov states that the recruitment of participants for this trial is ongoing and has been since December 10th, 2021. The most recent update to the study's information was on November 3rd 2022."
Would I meet the qualifications to partake in this clinical experiment?
"Patients must fit the parameters of 18 to 130 years old and possess locally advanced or metastatic solid tumours in order to partake in this experiment. Approximately 115 individuals will be accepted into the study."
What are the usual applications of AZD0171?
"AZD0171 is frequently prescribed for malignant peritoneal neoplasm and has been tested as a treatment for conditions including untreated cases of anthracycline-containing therapy."
Has AZD0171 been granted permission by the FDA?
"The safety of AZD0171 was rated a 2 since there is evidence that suggests its safe, however no data exists to prove it's efficacy."
Could you elucidate on the additional research that has been done utilizing AZD0171?
"AZD0171 was first explored by City of Hope Comprehensive Cancer Center back in 1997, and since then 1956 clinical trials have been brought to a successful close. At present, 1389 independent studies are underway with numerous being conducted out of Newton, Massachusetts."
Share this study with friends
Copy Link
Messenger